The science of biotechnology is tough. R&D can be unpredictable, and most products need regulatory approval before they can be […]
Dyadic founder fights to regain control of company Read Post »
Apologies for light posting as of late. I’ve been buried deep in revisions to Building Biotechnology and prepping for an
The March 2008 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to
Journal of Commercial Biotechnology — March 2008 Read Post »
Posting has been light lately — I’ve been working hard on revising Building Biotechnology. Off to the NIH next week
Two new biotechnology books: I’m proud to announce two new books featuring international best practices in biotechnology business development and
Guest content from John Avellanet, managing director and principal of Cerulean Associates: Follow-on biologics are a foregone conclusion in the
Browsing around the Biotechnology Industry Organization site late last night, I was surprised to find that BIO’s press release section
Browsing around the Biotechnology Industry Organization site late last night, I was surprised to find that BIO’s press release section
I’ll be at Rutgers on February 29th, giving a talk on biotechnology entrepreneurship. My objective is to dispel the popular
The following appeal for generic biologic legislation was sent in from Insmed via youtube. I’ve posted previously on the challenges
Get new actionable insights and updates from BiotechBlog
